JO
ZVRA icon

John Overdeck’s Zevra Therapeutics ZVRA Stock Holding History

John Overdeck’s Portfolio ZVRA Stock Details ZVRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$935K Buy
65,208
+12,772
+24% +$142K ﹤0.01% 3666
2026
Q1 		$489K Sell
52,436
-13,200
-20% -$119K ﹤0.01% 3761
2025
Q4 		$588K Buy
+65,636
New +$621K ﹤0.01% 3217
2019
Q1 		– Sell
-681
Closed -$19K – 3538
2018
Q4 		$19K Buy
+681
New +$27.6K ﹤0.01% 2889

Other funds holding ZVRA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

John Overdeck's ZVRA Position: Q2 2026 in Review

John Overdeck increased its Zevra Therapeutics (ZVRA) stake by 24% in Q2 2026, buying an estimated $142K and bringing the position to 65,208 shares worth $935K. The position accounts for ﹤0.01% of the portfolio, ranked #3666.

John Overdeck first reported a position in ZVRA in Q4 2018 and has held it in 4 quarters since. 156 funds tracked by Wall St. Rank hold ZVRA as of Q2 2026.

  • John Overdeck held 65,208 shares of Zevra Therapeutics worth $935K as of Q2 2026.
  • John Overdeck bought 12,772 Zevra Therapeutics shares in Q2 2026, an estimated $142K.
  • Zevra Therapeutics made up ﹤0.01% of John Overdeck's portfolio in Q2 2026, its #3666 holding.
  • John Overdeck first reported a position in Zevra Therapeutics in Q4 2018 and has held it in 4 quarters since.
  • 156 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q2 2026.

Based on Two Sigma Investments's 13F filing for Q2 2026, filed 14 Aug 2026.